EUCTR2008-005260-14-DE进行中（未招募）不适用
A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI-91 in patients with mild to moderate Alzheimer’s Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- AC Immune SA
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with a documented diagnosis of probable Alzheimer’s Disease” according to NINDS-ADRDA criteria supported by the results of a brain MRI scan made within one year of screening
- •- Patients with MMSE 18 – 26 at screening
- •- Male and female patients of age 40-85 years
- •- Patients cared for by a reliable caregiver either living-in or visiting on a daily basis to assure compliance, assist with clinical assessments to make sure that safety issues are reported
- •- Women must be post-menopausal for at least one year, surgically sterilised or using reliable contraceptive measures, eg. oral contraceptive or double-barrier method
- •- Patients who in the opinion of the investigator are likely to cooperate with the requirements of the study, able to hear, see and speak adequately to conduct the assessments and able to swallow the study medication
- •- Patients receiving stable dose of acetylcholinesterase inhibitors for at least 4 months prior to screening.
- •- Patients and caregivers must be fluent in German and able to comply with all study procedures
- •- Patients giving written informed consent (ability to give consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 46
排除标准
- •- Clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of SGOT, SGPT or creatinine
- •- Patients with elevated prothrombin or partial thromboplastin time
- •- Patients with a major depressive episode within the past 2 years or a history of recurrent major depression or a history of bipolar disorders according to DSM-IV criteria
- •- Patients with a Hamilton Depression (17 Item) Scale total score of 14 or greater or an individual item score of 3 or greater on Depressed Mood, Feelings of Guilt or Suicide at screening.
- •- Past or present history of abuse of drugs or alcohol
- •- Patients with stroke or myocardial infarction within the past year
- •- Participation in a trial of another investigational drug within the last three months prior to screening
- •- Patients with other medical conditions which may influence cognitive performance e.g. Parkinson’s disease, normal pressure hydrocephalus, progressive supranuclear palsy brain tumor, recurrent seizures, subdural hematoma, multiple sclerosis, severe head injury with coma lasting for more than a day
- •- Patients with an alternative cause for dementia as determined by MRI scan within 1 year prior to the study, at a time when the patient was known to be demented. Diffuse periventricular white matter changes need not result in exclusion.
- •- Patients with vascular dementia according to NINDS-AIREN criteria
- •- Patients with Vitamin B12 or folate deficiency or hypothyroidism unless on replacement therapy for at least three months.
- •- Patients with a positive HIV and/or syphilis test at screening
- •- Patients with closed angle glaucoma
- •- Patients with symptomatic prostatic hypertrophy
- •- Patients with any unstable medical condition which might alter the ability to complete the clinical study.
- •- Patients with moderate or severe renal or hepatic impairment
- •- Patients unable to undergo MRI examination for any reason, including claustrophobia
- •- Patients who are lactating, pregnant or planning to be pregnant, or who have a positive pregnancy test at screening (women of childbearing potential)
- •- Patients receiving anticoagulant drugs
- •- Patients receiving anticholinergic drugs, eg oxybutinin, tolteridone, tricyclic antidepressants
- •- Patients receiving neuroleptic drugs other than atypical antipsychotics
- •- Patients receiving pirenzepine
- •- Patients receiving antioxidants including Coenzyme Q10 or high dose vitamins (5 times the recommended dose of Vitamin E or Vitamin C)
- •- Patients receiving MAO-A or MAO-B inhibitors eg selegiline, rasagiline
- •- Patients receiving putative cognitive enhancers other than acetylcholinesterase inhibitors (eg ergoloid mesylates, nimodipine, piracetam, gingko biloba).
- •- Patients receiving memantine currently or previously
- •- Patients with a major psychiatric illness within the past 5 years
- •- Patients who have been hospitalized involuntarily or at the request of the caregiver
研究者
相似试验
进行中（未招募）
不适用
A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI 91 in patients with mild to moderate Alzheimer’s Diseasemild to moderate Alzheimer’s DiseaseMedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2008-005260-14-ATAC Immune SA60
已完成
2 期
The effect of saffaron tablet on the level of inflammatory markers with knee osteoarthritis patientsKnee Osteoarthritis.Bilateral primary osteoarthritis of kneeIRCT2016091029777N1Vice chancellor for research, Golestan University of Medical Sciences80
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseEUCTR2006-004111-22-GRovartis Pharma Services AG146
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseCushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily femalesMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseEUCTR2006-004111-22-DEovartis Pharma Services AG100
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseCushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily femalesEUCTR2006-004111-22-DKovartis Pharma Services AG146